Skip to main content
Premium Trial:

Request an Annual Quote

Applied Imaging, US Food and Drug Administration, Vysis

Premium

Applied Imaging has received 510(k) clearance from the US Food and Drug Administration to market its Ariol Her-2/neu FISH application, which is designed to detect Her-2/neu gene amplification in breast cancer biopsy samples using fluorescence in situ hybridization, the company said.

The application is the final addition to the breast cancer panel on the Ariol system which also includes assays for Her-2/neu immunohistochemistry, Her-2/neu FISH, estrogen receptor, and progesterone receptor.

The Ariol Her-2/neu FISH application uses the PathVysion Her-2/neu DNA Probe Kit from Vysis, a subsidiary of Abbott Labs.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.